UK Markets closed
  • NIKKEI 225

    29,106.01
    +505.60 (+1.77%)
     
  • HANG SENG

    26,038.27
    -93.76 (-0.36%)
     
  • GOLD FUTURES

    1,795.20
    -11.60 (-0.64%)
     
  • DOW

    35,853.69
    +112.54 (+0.31%)
     
  • BTC-GBP

    45,186.19
    -782.98 (-1.70%)
     
  • CMC Crypto 200

    1,499.89
    -5.26 (-0.35%)
     
  • Nasdaq

    15,258.26
    +31.56 (+0.21%)
     
  • ^FTAS

    4,149.81
    +31.88 (+0.77%)
     

Outlook on the Plasma Fractionation Global Market to 2027 - Impact of COVID-19 on the Industry - ResearchAndMarkets.com

·4-min read

DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Global Plasma Fractionation Market" report has been added to ResearchAndMarkets.com's offering.

Plasma fractionation is a definite as process of separating various components of blood plasma which are used for producing different therapeutic plasma products. These plasma products are used for treating different medical conditions. For instance, coagulation factor VIII is a plasma derivative which is primarily used for treatment & prophylaxis of hemophilia. Also, it is also used to prevent excessive blood loss during surgical procedures. Similarly, immunoglobulins are used in the treatment of primary & secondary immune deficiencies.

The increase in adoption of immunoglobulins in various therapeutic applications is expected to boost the growth of global plasma fractionation market over the forecast period. Thus, the increasing use of immunoglobulin will magnify its dominance & improve market prospects. Immunoglobulins are a glycoprotein molecule which are derived through plasma & act as antibodies. From past few years, diagnosis rate of various immunological diseases has increased due to technological advancements. Also, the rise in genetic research for characterizing & diagnosing immunodeficiency will raise the clinical need for immunoglobulins due to the increase in number of diagnosed patients.

Furthermore, the increase in focus on establishing advanced plasma fractionation facilities by key player. For instance, in 2019, Kedrion Biopharma had announced that the company received approval from U.S. Food and Drug Administration (USFDA) for establishing a plasma manufacturing facility in Melville which would be dedicated to producing plasma patients. The growing establishments of such facilities is expected to drive the global plasma fractionation market growth.

Stringent regulatory policies may hamper the growth of global plasma fractionation market growth over the forecast period. As plasma products are separated from blood, the product is strictly regulated by regulatory authorities. Stringent rules and regulations pertaining to the manufacturing facility, source of whole blood, isolation process among others can hamper the market growth.

Companies Mentioned

  • Grifols S.A

  • CSL Ltd.

  • Octapharma AG

  • Baxalta Incorporated

  • Takeda Pharmaceutical Company Ltd

  • Kedrion S.p.A

  • Sanquin

  • Biotest AG

Impact of COVID-19 on Market

Spread of COVID-19 has affected every industry across the globe. For instance, after COVID-19 was declared as a pandemic by the World Health Organization (WHO), countries worldwide announced nationwide lockdowns to observe social distancing as a measure to contain the spread. This leads to disruption, challenges, and changes in each sector of every industry. Also, the global plasma fractionation market was negatively impacted by the pandemic, due to the decrease in number of blood donations and plasma collections.

Key Questions Addressed by the Report

  • What are the Key Opportunities in Global Plasma Fractionation Market?

  • What will be the growth rate from 2019 to 2027?

  • Which segment/region will have highest growth?

  • What are the factors that will impact/drive the Market?

  • What is the competitive Landscape in the Industry?

  • What is the role of key players in the value chain?

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Plasma Fractionation Market Outlook

4.1 Overview

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.3 Porters Five Force Model

4.4 Value Chain Analysis

5 Global Plasma Fractionation Market, By Product

5.1 Y-o-Y Growth Comparison, By Product

5.2 Global Plasma Fractionation Market Share Analysis, By Product

5.3 Global Plasma Fractionation Market Size and Forecast, By Product

5.3.1 Albumin

5.3.2 Immunoglobulins

5.3.3. Coagulation factor VIII

5.3.4 Coagulation factor IX

6 Global Plasma Fractionation Market, By Sector

6.1 Y-o-Y Growth Comparison, By Sector

6.2 Global Plasma Fractionation Market Share Analysis, By Sector

6.3 Global Plasma Fractionation Market Size and Forecast, By Sector

6.3.1 Public Sector

6.3.2 Private Sector

7 Global Plasma Fractionation Market, By Region

7.1 Global Plasma Fractionation Market Share Analysis, By Region

7.2 Global Plasma Fractionation Market Share Analysis, By Region

7.3 Global Plasma Fractionation Market Size and Forecast, By Region

8 North America Plasma Fractionation Market Analysis and Forecast (2020 - 2027)

9 Europe Plasma Fractionation Market Analysis and Forecast (2020 - 2027)

10 Asia Pacific Plasma Fractionation Market Analysis and Forecast (2020 - 2027)

11 Latin America Plasma Fractionation Market Analysis and Forecast (2020 - 2027)

12 Middle East Plasma Fractionation Market Analysis and Forecast (2020 - 2027)

13 Competitive Analysis

13.1 Competition Dashboard

13.2 Market share Analysis of Top Vendors

13.3 Key Development Strategies

14 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ancog8

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005608/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting